Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails
A phase 1b/2 trial found that the oral CBP–β-catenin inhibitor E7386 combined with lenvatinib produced durable responses in advanced endometrial cancer patients whose disease had progressed after platinum chemotherapy and anti-PD-(L)1 immunotherapy.
Read moreDetails



















